Skip to content

LSD research published in 2021

Page 2 of 3: studies 21 to 40 of 56, newest first. Back to the LSD overview

Studies

Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin

Frontiers in Pharmacology July 13, 2021 Friederike Holze, Isidora Avedisian, Nimmy Varghese et al. 66 citations

The psychedelic lysergic acid diethylamide (LSD) has experienced a revival in research, including clinical trials that evaluate LSD-assisted psychotherapy. LSD induces perceptual alterations and influences emotion processing in ways that may support psychotherapy. Here, we investigated the effects of LSD on emotional empathy and mediating role of the serotonin 5-hydroxytryptamine-2A (5-HT 2A )...

Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD

Elife July 12, 2021 Joshua B. Burt, Katrin H. Preller, Murat Demirtaş et al. 49 citations

Psychoactive drugs can transiently perturb brain physiology while preserving brain structure. The role of physiological state in shaping neural function can therefore be investigated through neuroimaging of pharmacologically induced effects. Previously, using pharmacological neuroimaging, we found that neural and experiential effects of lysergic acid diethylamide (LSD) are attributable to...

Registered clinical studies investigating psychedelic drugs for psychiatric disorders.

Journal of Psychiatric Research July 1, 2021 Ashley N. Siegel, Shakila Meshkat, Katie Benitah et al. 101 citations

Psychedelics are a hallucinogenic class of psychoactive drugs with the primary effect of activating non-ordinary states of consciousness. Due to the positive preliminary findings of these drugs in the treatment of psychiatric disorders, the number of registered clinical studies has risen significantly. In this paper, clinical studies registered on clinicaltrials.gov that evaluate the treatment...

LSD induces increased signalling entropy in rats’ prefrontal cortex

bioRxiv (Cold Spring Harbor Laboratory) June 23, 2021 Aurora Savino, Charles D. Nichols 2 citations preprint

Abstract Psychedelic drugs are gaining attention from the scientific community as potential new compounds for the treatment of psychiatric diseases such as mood and substance use disorders. The 5-HT 2A receptor has been identified as the main molecular target, and early studies pointed to an effect on the expression of neuroplasticity genes. Analysing RNA-seq data from the prefrontal cortex of...

Early LSD treatment in Denmark from 1960 to 1974: An analysis of possible and long-lasting changes in the adult personality following psychedelic treatment. A historical retrospective cohort study.

Medicine June 11, 2021 Jens Knud Larsen

In view of the renewed interest in psychedelics in psychiatry it is timely to analyze psychedelic treatment in historical cohorts. Recently the therapeutic efficacy of psychedelics has been linked to the so-called phenomenon of "connectedness." The aim of the present study was to explore whether long-lasting personality changes were observed in any of the 151 Danish psychiatric patients who...

The Promise and Demise of LSD Psychotherapy in Norway

Social History of Medicine May 28, 2021 Per Haave, Willy Pedersen 7 citations

Abstract In the early-to-mid 1960s, there was considerable use of LSD in psychotherapy in several countries. However, its use gradually levelled off. Two explanations have been suggested: The first revolves around a ‘moral panic’ in the wake of the introduction of cannabis and LSD by subcultural youth groups. The second focuses on the lack of proof for the therapeutic efficacy of LSD at a time...

Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.

Scientific Reports May 25, 2021 Patrick Vizeli, Isabelle Straumann, Friederike Holze et al. 54 citations

Lysergic acid diethylamide (LSD) is a classic psychedelic substance that is used recreationally and investigated in psychiatric research. There are no pharmacogenetic studies on LSD. In vitro metabolic studies indicate that several cytochrome P450 (CYP) isoforms (e.g., CYP2D6, CYP1A2, and CYP2C9) are involved in LSD metabolism, but in vivo data are scarce. The present study examined the...

Separating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA

Drug Testing and Analysis May 22, 2021 Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al. 12 citations

Abstract Lysergic acid diethylamide (LSD) is a potent psychoactive substance that has attracted great interest in clinical research. As the pharmacological exploration of LSD analogs continues to grow, some of those analogs have appeared on the street market. Given that LSD analogs are uncontrolled in many jurisdictions, it is important that these analogs be differentiated from LSD. This report...

DOI: 10.1002/dta.3103 (opens in new tab) Electron ionization Gas chromatography–mass spectrometry Derivatization Tandem mass spectrometry

Supporting the Patient on LSD Day

AJN, American Journal of Nursing May 19, 2021 Betsy Todd

Editor's note: From its first issue in 1900 through to the present day, AJN has unparalleled archives detailing nurses' work and lives over more than a century. These articles not only chronicle nursing's growth as a profession within the context of the events of the day, but also reveal prevailing societal attitudes about women, health care, and human rights. Today's nursing school curricula...

The Potential Role of Psychedelic Drugs in Mental Health Care of the Future

Pharmacopsychiatry May 12, 2021 Gerhard Gründer, Henrik Jungaberle 32 citations

Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), or dimethyltryptamine (DMT), as well as psychoactive drugs that trigger phenomenologically- related experiences like 3,4-methylenedioxymethamphetamine (MDMA) and ketamine, belong to the most promising treatment approaches in contemporary psychiatry. Psychedelic-assisted psychotherapy is not only a new...

MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers

Trials April 23, 2021 Robin J Murphy, Rachael Sumner, William Evans et al. 23 citations

BACKGROUND: Regular ingestion of sub-hallucinogenic doses of psychedelics, referred to as "microdosing", has gained increasing popularity and attention in the press and in online forums, with reported benefits across multiple cognitive and emotional domains. Rigorously controlled studies to date, however, have been limited in scope and have failed to produce results comparable to those reported...

Back to the Future — The Therapeutic Potential of Psychedelic Drugs

New England Journal of Medicine April 14, 2021 Jeffrey A. Lieberman 18 citations

In The Doors of Perception, Aldous Huxley described his trial of mescaline as "the most extraordinary and significant experience available to human beings this side of the Beatific Vision." His exegesis was preceded by the synthesis of the hallucinogen lysergic acid diethylamide (LSD) by Sandoz chemist Albert Hoffman in 1938 and was followed by Hoffman's extraction of psilocybin from Psilocybe...

Lysergic acid diethylamide (LSD) promotes social behaviour through 5-HT 2A and ampa in the medial prefrontal cortex (MPFC)

European Psychiatry April 1, 2021 Athanasios Markopoulos, Antonio Inserra, Danilo de Gregorio et al. 5 citations

Introduction Autism Spectrum Disorder and Social Anxiety Disorder are mental illnesses characterized by a dysfunction in social behavior (SB); a phenomenon largely mediated by the medial prefrontal cortex (mPFC). Clinical studies have demonstrated that lysergic acid diethylamide (LSD), a partial agonist of the 5-HT 2A receptor, can promote SB. However, its mechanism of action on SB is unknown....

Psychedelics and psychiatric disorders: A emerging role

European Psychiatry April 1, 2021 Clayton Peixoto, Fabiano Santos, Daianne Cardinalli Rêgo et al. 1 citation

Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin and mescaline act pharmacologically as agonists at the 5-HT2A receptor. The entactogens like methylenedioxymethamphetamine (MDMA), acts as a serotonin, dopamine and noradrenaline agonist. All of these drugs are potential candidates in the...

Psychedelics: A new era of treatment?

European Psychiatry April 1, 2021 S. Torres 2 citations

Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. In 1950, after LSD’s discovery by Hofmann, psychedelics enjoyed a short-lived relationship with psychiatry, before prohibitive legislature emerging in response to the recreational use in the mid-1960s....

LSD and ketanserin and their impact on the human autonomic nervous system

Psychophysiology March 27, 2021 Sebastian Olbrich, Katrin H. Preller, Franz X. Vollenweider 34 citations

Abstract The interest in lysergic acid diethylamide (LSD) has sparked again due to its supposed positive effects on psychopathological conditions. Yet, most research focuses on the actions of LSD on the central nervous system. The interaction with the autonomic nervous system (ANS) has been neglected so far. Therefore, the aim was to assess the effects of LSD and the serotonin 2A receptor...

DOI: 10.1111/psyp.13822 (opens in new tab) Ketanserin Placebo Autonomic nervous system Analysis of variance +6

Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action

Journal of Psychopharmacology March 19, 2021 Rafael G. Dos Santos, Jaime Ec Hallak, Glen B. Baker et al. 51 citations

Major depressive disorder (MDD) is among the most prevalent mental health disorders worldwide, and it is associated with a reduced quality of life and enormous costs to health care systems. Available drug treatments show low-to-moderate response in most patients, with almost a third of patients being non-responders (treatment-resistant). Furthermore, most currently available medications need...

On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review

ACS Pharmacology & Translational Science March 11, 2021 Richard J. Zeifman, Nikhita Singhal, Leah Breslow et al. 60 citations

Use of classic psychedelics (e.g., psilocybin, ayahuasca, and lysergic acid diethylamide) is increasing, and psychedelic therapy is receiving growing attention as a novel mental health intervention. Suicidality remains a potential safety concern associated with classic psychedelics and is, concurrently, a mental health concern that psychedelic therapy may show promise in targeting. Accordingly,...

LSD et soins palliatifs dans les années 1960, un rendez-vous manqué ?

March 9, 2021 Z. Dubus

Resume Decouvert en 1943 par le chimiste suisse Albert Hofmann, le LSD fut rapidement reconnu pour ses effets therapeutiques, notamment dans le cadre de la fin de vie. Puissant antalgique, il permettait aux patients en phase terminale de cancer d’apprehender leur propre mort avec plus de serenite et favorisait la communication avec les proches et le personnel soignant. Faisant partie des...